Investigating how a specific leptin receptor variant affects bacterial pneumonia outcomes
Q223R Leptin Receptor Polymorphism in Bacterial Pneumonia
This study is looking at how a specific gene change might affect people with bacterial pneumonia, especially those infected with Klebsiella pneumoniae, to see if it influences their immune response and lung damage, with the hope of finding better treatments for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10993097 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific variant of the leptin receptor (Q223R) in patients suffering from bacterial pneumonia, particularly caused by Klebsiella pneumoniae. The study aims to explore how this genetic polymorphism influences neutrophil recruitment and the subsequent lung damage that can occur during severe infections. By examining the immune response and the mechanisms behind excessive neutrophil activity, the research seeks to identify potential therapeutic targets to improve patient outcomes. Patients with this polymorphism may be monitored to better understand their responses to bacterial infections and treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with bacterial pneumonia, especially those who may carry the Q223R leptin receptor polymorphism.
Not a fit: Patients without bacterial pneumonia or those who do not have the Q223R leptin receptor variant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with bacterial pneumonia, particularly those with the Q223R leptin receptor variant.
How similar studies have performed: Previous research has indicated that genetic variations like the leptin receptor polymorphism can significantly impact immune responses, suggesting that this approach may yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Mancuso, Peter — University of Michigan at Ann Arbor
- Study coordinator: Mancuso, Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.